HDAC10 and lymphoma: Our data reveal that human leukemia cells of the lymphoid lineage and lymphomas cells succumb to HDAC10 inhibition, elucidate the underlying molecular mechanisms, and disclose pharmacodynamic markers to assess anti-leukemic activities of HDAC10 inhibitors.